Partnerships, Licensing, Investments and M&A Deals and Trends for March 2019 in Pharmaceuticals

GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends for March 2019 in Pharmaceuticals” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2019. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

Analysis of the market trends for the pharmaceutical industry in the global arena.

Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.

Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.

Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.

Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.

Analysis of partnership and licensing deals based on clinical stage of development of products.

Summary of the pharmaceutical deals globally in the six months.

Information on the top deals happened in the pharmaceutical industry.

Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

Enhance your decision making capability in a more rapid and time sensitive manner.

Find out the major deal performing segments for investments in your industry.

Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.

Identify companies that are aggressively looking to raise capital in the market

Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.

Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.

Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.

Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.

Identify growth segments and opportunities in each region within the industry.

Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal ...

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 7

2 Pharmaceuticals & Healthcare, Global, Deal Summary 10

2.1 Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2019 10

2.2 Pharmaceuticals & Healthcare, Global, Major Deals, March 2019 12

2.2.1 Medtronic Raises USD7.9 Billion in Public Offering Of Senior Notes 12

2.2.2 Daiichi Sankyo Enters into Collaboration with AstraZeneca 12

2.2.3 Pfizer Raises USD5 Billion in Public Offering of Notes 13

2.2.4 Merck Raises USD5 Billion in Public Offering of Notes 13

2.2.5 AstraZeneca Raises USD3.5 Billion in Private Placement of Shares 14

2.3 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2019 15

2.4 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2019 16

3 Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 17

3.1 Pharmaceuticals & Healthcare, Global, M&A, March 2019 17

3.1.1 Top M&A Deals in March 2019 18

3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals by Therapy Area, October 2018 – March 2019 19

3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, March 2019 20

3.2.1 Top Equity Offering Deals in March 2019 21

3.2.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, October 2018 – March 2019 22

3.3 Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital Deals, March 2019 23

3.3.1 Top PE/VC Deals in March 2019 24

3.3.2 Pharmaceuticals & Healthcare, Global, PE/VC by Therapy Area, March 2019 25

3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, March 2019 26

3.3.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, June 2016–March 2019 28

3.3.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, June 2016–March 2019 29

3.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, March 2019 30

3.5 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, October 2018 – March 2019 31

3.6 Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Values (US$ m), March 2019 32

3.6.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals by Payment Mode, March 2019 33

3.7 Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), October 2018 – March 2019 34

3.8 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Number Of Deals, October 2018 – March 2019 36

3.9 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, Deal Values (US$ m), October 2018 – March 2019 37

3.10 Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2018 – March 2019 38

4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2019 40

4.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2019 40

4.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), March 2019 41

4.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Values (US$ m), October 2018 – March 2019 42

4.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payments and Milestone Payments (US$ m), October 2018 – March 2019 43

4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Values (US$ m), October 2018 – March 2019 45

4.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payments and Milestone Payments (US$ m), October 2018 – March 2019 47

4.6.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Deal Value, March 2019 48

4.6.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, March 2019 49

4.6.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, March 2019 49

5 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 50

5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, March 2019 50

5.1.1 Oncology – Deals of the Month 51

5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, March 2019 53

5.2.1 Central Nervous System – Deals of the Month 54

5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, March 2019 56

5.3.1 Infectious Diseases – Deals of the Month 57

5.4 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, March 2019 58

5.4.1 Cardiovascular – Deals of the Month 59

5.5 Pharmaceuticals & Healthcare, Global, Immunology Deals, March 2019 61

5.5.1 Immunology – Deal of the Month 62

5.6 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, March 2019 64

5.6.1 Gastrointestinal – Deals of the Month 65

5.7 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, March 2019 67

5.7.1 Metabolic Disorders – Deals of the Month 68

6 Deal Summary by Geography 70

6.1 Pharmaceuticals & Healthcare, North America Deals, March 2019 70

6.1.1 North America – Deals of the Month 71

6.2 Pharmaceuticals & Healthcare, Europe, Deals, March 2019 73

6.2.1 Europe – Deals of the Month 74

6.3 Pharmaceuticals & Healthcare, Asia-Pacific, Regional Deals, March 2019 76

6.3.1 Asia-Pacific – Deals of the Month 77

6.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, March 2019 79

6.4.1 Rest of the World – Deals of the Month 80

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 82

7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, October 2018 – March 2019 82

7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, October 2018 – March 2019 83

8 Further Information 84

8.1 Methodology 84

8.2 About GlobalData 85

8.3 Contact Us 85

8.4 Disclosure information 85

8.5 Disclaimer 86

List of Tables

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 ...

1.1 List of Tables

Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 11

Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2019 12

Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2019 16

Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 18

Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2019 18

Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2018 – March 2019 19

Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 21

Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2019 21

Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 22

Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 24

Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2019 24

Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2018 – March 2019 25

Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2019 27

Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 28

Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2018 – March 2019 29

Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 30

Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 31

Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 – March 2019 32

Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2019 33

Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 – March 2019 35

Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2018 – March 2019 37

Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2018 – March 2019 39

Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 40

Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 – March 2019 41

Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 42

Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2019 44

Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2018 – March 2019 46

Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2019 48

Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2019 48

Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2019 49

Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2019 49

Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 51

Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 54

Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 57

Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 59

Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 62

Table 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 65

Table 38: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 68

Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 71

Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 74

Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 77

Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 80

Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 82

Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 83

List of Figures

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 10

Figure ...

1.2 List of Figures

Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 10

Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2019 15

Figure 3: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2019 16

Figure 4: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 17

Figure 5: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2018 – March 2019 19

Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 20

Figure 7: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 22

Figure 8: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 23

Figure 9: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2018 – March 2019 25

Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2019 26

Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2019 27

Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 28

Figure 13: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 30

Figure 14: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 31

Figure 15: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 – March 2019 32

Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 – March 2019 34

Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2018 – March 2019 36

Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2018 – March 2019 37

Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2018 – March 2019 38

Figure 20: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 40

Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 – March 2019 41

Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 42

Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2018 – March 2019 43

Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2018 – March 2019 45

Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2018 – March 2019 46

Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2019 47

Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 50

Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 53

Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 56

Figure 30: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 58

Figure 31: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 61

Figure 32: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 64

Figure 33: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 67

Figure 34: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 70

Figure 35: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 73

Figure 36: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 76

Figure 37: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 79

Figure 38: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 82

Figure 39: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2018 – March 2019 83

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports

We find GlobalData’s reports and models very helpful.

  DRI Capital